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Gelatinase A is a key enzyme in the family of matrix metalloprote-
inases (matrixins) that are involved in the degradation of the ex-
tracellular matrix. As this process is an integral part of tumour
cell metastasis and angiogenesis, gelatinase is an important target
for therapeutic intervention. The X-ray crystal structure of the ge-
latinase A catalytic domain (GaCD) complexed with batimastat
(BB94), a hydroxamate inhibitor, shows an active site with a large
S1' specificity pocket. The structure is similar to previously solved
structures of stromelysin catalytic domain (SCD) but with differ-
ences in VR1 and VR2, two surface-exposed loops on either side of
the entrance to the active site. Comparison of GaCD with other
members of the matrix metalloproteinase (MMP) family highlights
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the conservation of key secondary structural elements and the sig-
nificant differences in the specificity pockets, knowledge of which
should enhance our ability to design specific inhibitors for this im-
portant anticancer target.
Key words: inhibitor, matrixin, matrix metalloproteinase-3 (MMP-3),
stromelysin-1, MMP-2, gelatinase A, metzincin.
INTRODUCTION
Gelatinase is a matrix metalloproteinase that degrades the major pro-
tein components of the extracellular matrix in connective tissues, such as
type IV collagen.1 As degradation of the extracellular matrix is an essential
step in tumour cell metastasis and angiogenesis, intensive efforts have been
devoted to the discovery of matrix metalloproteinase inhibitors for thera-
peutic use in the treatment of cancer. Batimastat (BB94) represents a class
of inhibitors that were developed by modifying the peptide sequence at the
cleavage site of substrates and introducing a hydroxamic acid group as the
ligand for the catalytic zinc.2 Such peptide hydroxamates are, in general,
potent, broad-spectrum matrix metalloproteinase inhibitors. Batimastat
has been shown to inhibit the metastatic spread of tumour cells3,4 and has
been tested clinically for the treatment of malignant effusions associated
with thoracic and peritoneal neoplasms.5
Matrix metalloproteinases are homologous zinc endopeptidases belonging
to the »metzincin« superfamily.6 They share a zinc-binding HExxHxxGxxH-
consensus motif and a strictly conserved methionine-containing 1,4-turn
(Met-turn) adjacent to the catalytic zinc ion. Matrix metalloproteinase have
three discrete domains, a propeptide which is cleaved during activation, a
zinc-binding catalytic domain, and a carboxy-terminal hœmopexin-like do-
main (not present in matrilysin) involved in substrate recognition. Studies
of the catalytic and hœmopexin-like domains of recombinant matrix metal-
loproteinases7–11 show that the catalytic domains show similar activity, spe-
cificity and sensitivity against synthetic substrates as the parent enzymes,
and so are appropriate models for the structure-based design of inhibitors of
the full-length proteins.
The three-dimensional structures of several matrix metalloproteinases
have now been published. X-ray crystallographic and NMR studies have
produced structures of the catalytic domains of fibroblast collagenase,12–15
neutrophil collagenase,16–21 matrilysin,22 stromelysin-123–29 and the C-trun-
cated proenzyme of stromelysin-1.24 Crystal structures of complexes of stro-
melysin-1 and membrane type 1 matrix metalloproteinase (MMP-14) and
naturally occurring tissue inhibitors of metalloproteinases-1 and -2, respec-
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tively, have also been disclosed recently.28,30 Attempts at solving the crystal
structures of matrix metalloproteinases containing additional domains have
met only limited success. To date, only the full-length structure of porcine
collagenase containing the C-terminal domain has been reported.31
A unique 19 kDa insert made up of three tandem repeats of a fibronectin
type II unit (the »fibronectin insert«) occurs within the catalytic domain of
both gelatinase A and gelatinase B. On the basis of homology, we re-engi-
neered gelatinase A at the gene level by deleting this insert and reconnect-
ing the two fragments of the catalytic domain to form a shorter gelatinase A
catalytic domain (GaCD).32 The reconstructed GaCD is very similar to the
catalytic domains of stromelysins and collagenases, and has activities simi-
lar to that of full-length gelatinase A against synthetic substrates and the
natural protein substrate gelatin.33
We now report the first X-ray crystal structure of the human gelatinase
A catalytic domain protein complexed with the inhibitor batimastat (BB94).
The structure confirms some conclusions based on previously generated ho-
mology models,34 but further provides an accurate structural basis for the
design of the next generation of inhibitors with improved selectivity and
bioavailability. The detailed insights into the interaction of BB94 with gela-
tinase A, and comparisons with other matrix metalloproteinase crystal
structures,35 can be used to rationalize observed differences in affinity
among known inhibitors.
EXPERIMENTAL
Expression, Crystallisation and X-ray Data Collection
The expression and purification of gelatinase A catalytic domain has been de-
scribed previously.33 The protein GaCD used in the structural determination is
modified slightly from that originally described by changing residues 105–110
(187–191 stromelysin numbering, the last glycine being referred to as 190A in
GaCD) from GFCPDQ to SLGKGV, thus eliminating the cysteine in the sequence.
The two constructs GaCD and GCD showed similar enzymatic activity.
Crystals suitable for X-ray analysis were grown by the hanging-drop vapour dif-
fusion method with a 15 mg/ml protein solution in 50 mM Tris/HCl in the presence
of the inhibitor (which was allowed to equilibrate in the concentrated protein solu-
tion for several days), 10 M ZnCl2, 10 mM CaCl2, and PEG8K. Diffraction data
were collected on a MARResearch image plate detector at the Synchrotron Radiation
Source, Daresbury, UK. The program DENZO36 was used to establish the reference
orientation of the crystal, to reduce the image plate data, and to refine cell and data
collection parameters. Further merging, scaling, correction, and processing of the
data were carried out using the program SCALEPACK.36 A summary of the crystal
and X-ray diffraction data is presented in Table I.
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Structure Analysis
The gelatinase-inhibitor complex was solved by molecular replacement using the
AMORE.37 The catalytic domain of stromelysin (SCD) has a sequence identity of ap-
proximately 60% with GaCD and hence the coordinates of SCD complexes previously
solved in this laboratory26,27,38 (minus the inhibitor, metal ions, and water molecules)
was used as the initial models. Computation of the rotation function revealed three
peaks above the threshold level of 0.5 S, where S is the height of the largest rotation
peak. The top solution (which was selected) was twice the height of the second and
third solutions. A single molecule in the asymmetric unit was consistent with the ex-
pected number of target molecules in the unit cell. The rotation function solution
produced just one significant translation function peak for space group P4122. This
solution had a correlation coefficient of 0.49 with an R factor of 0.45. After rigid-body
refinement using the FITING routine in AMORE, these values improved to 0.59 and
0.42 respectively.
Model Building and Refinement
A sample of 555 out of 5551 unique reflections from the processed data were se-
lected from thin resolution shells using the program DATAMAN,39 and excluded
from the refinement. The agreement between calculated and observed structure fac-
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TABLE I
Crystallographic data and refinement statistics
Space group P4122
Unit cell a = b = 84.83 Å; c = 57.90 Å;
a = b = g = 90°
Number of molecules per asymmetric unit 1
Wavelength / Å 0.88
Maximum resolution / Å 2.8
Unique reflections 5551









Rmerge = I – I/I, where I is the intensity of an individual measurement, and I is the
mean intensity of this reflection. bRcryst = Fo – Fc/Fo, where Fo and Fc are the
observed and calculated structure factor amplitudes, respectively. cRMS deviations of bond
lengths and angles in the refined structure from ideal values.42
tors for these reflections, Rfree,40 was used to monitor the course of the refinement
procedure. Several cycles of rigid-body refinement in X-PLOR,41 using force-field pa-
rameters derived by Engh and Huber,42 were carried out and the resulting electron
density map, viewed using the program O,43 showed strong peaks in the 2Fo–Fc and
Fo–Fc maps for two zinc and two calcium atoms together with electron density in the
active site for the inhibitor. Positive and negative density in the Fo–Fc map indicated
differences in amino acid sequence between SCD and GaCD. The correct sequence
for GaCD was modelled into the 2 Fo  – Fc  density. A glycine residue (190A) was in-
serted after residue 190 and residues 224–226 were removed as density in these re-
gions (corresponding to VR1 and VR2) were both poor. Rigid-body refinement fol-
lowed by conventional positional and then temperature factor refinement with a
bulk-solvent correction gave Rfree = 0.336 and R = 0.278. This gave excellent density
for the third calcium and allowed the inhibitor to be unambiguously positioned in
the GaCD active site. Residues at the N- and C-termini were defined by good elec-
tron density and added to the model. Further rounds of refinement and modelling al-
lowed the variable regions, VR1 and VR2, at either side of the active site to be de-
fined, although there was still very poor density for Lys190. Water molecules coor-
dinating two of the calciums and the inhibitor were added to the model. The Rfree
and conventional R factor converged at 0.244 and 0.205 respectively.
RESULTS AND DISCUSSION
Overall Three-dimensional Structure
Figure 1 shows the structure of the catalytic domain of gelatinase A
(GaCD), defined in this study, compared to that of stromelysin catalytic do-
main (SCD).26,27 GaCD adopts the now familiar open-sandwich topology of
matrix metalloproteinases, in which two -helices are packed against a
twisted, five-stranded 	-sheet. The amphipathic helix A extends the full
length of the sheet and is inserted between parallel 	1 and 	2. The strands are
ordered 	2	1	3	5	4 in the sheet, with strand 	4 antiparallel to the others. He-
lix B contains the sequence HExxH, with the two histidines (201 and 205,
stromelysin numbering, see Figure 2) positioned to be ligands to the catalytic
zinc. A short turn at the conserved Gly208 brings His211 into a position in
which it can be a third ligand for the catalytic zinc. The remaining part of the
structure comprises turns and short strands together with helix C; these
contribute to the formation of a well-defined substrate binding cleft.
Comparison of GaCD with the SCD Complexes
A comparison of the sequences and structural features of GaCD and
other members of the matrixin family is shown in the JOY format48,49 gen-
erated using the program COMPARER50 (Figure 2). GaCD is most similar
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Figure 1. MOLSCRIPT44 representation of the structure of (a) GaCD complexed
with BB94 and (b) SCD complexed with INH-I.
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Figure 2. JOY format output45 of the structural alignment of matrix metalloprotei-
nases generated using COMPARER.46 The variable regions VR1 (189–193) and VR2
(224–231) are bounded by dashed lines. The numbering is relative to that used for
stromelysin. Protein codes are as follows: SCD, stromelysin catalytic domain com-
plex with U24522; GaCD, Gelatinase A catalytic domain; 1FBL, full-length porcine
synovial collagenase; 1HFC, human fibroblast collagenase catalytic domain; 1MMB,
human neutrophil collagenase catalytic domain; 1MMP, human matrilysin. The
alignment key is as follows: UPPER CASE, solvent inaccessible; lower case, solvent
accessible; bold type, hydrogen bond to main-chain amide; underline, hydrogen
bond to main-chain carbonyl; tilde, hydrogen bond to side-chain; italics, positive 
;
çedilla, disulphide bonded cysteine; breve, cis-peptide.
to SCD followed by the collagenases and then by matrilysin. The core re-
gions of GaCD show no significant difference to SCD. The main differences
between GaCD and SCD occur at the site of the insertion in VR1 and at the
three-residue deletion in VR2. Smaller differences are found in the region
135–140, which forms a loop between 2 and 3, and in the region 148–151,
which forms a loop between 3 and 4; these adopt different conformations
due to crystal packing. The N-terminus is more ordered than in SCD since it
interacts with an equivalent region in a symmetry-related molecule (1+x,
1+y, z), with residue Asp141 (between strands 2 and 3), the loop contain-
ing residues 170–172 (between strands 4 and 5), and residue Leu245 in
helix C, of the symmetry-related molecule.
Metal Coordination
The coordination of the catalytic Zn1 by His 201 N2, His205 N2 and
His211 Ne2, described above, is completed by both hydroxamate oxygens of
the inhibitor, in a distorted pentacoordinate geometry (Figure 3). A very si-
milar environment is apparent in the SCD hydroxamate complex.26,27 GaCD
also coordinates the other two zincs and two calciums in a similar fashion to
SCD. Thus, Zn2 is bound in a tetrahedral coordination by His151 N2,
Asp153 O2, His166 N2, and His179 N1. All three calciums are octahe-
drally coordinated by six ligands. Ca1 is bound by Asp158 Od1, Gly159 O,
Asp161 O (Gly161 in SCD), Leu163 O (Val163 in SCD), Asp181 Od2, and
Glu184 O2, Ca2 by Asp141 O, Gly173 O, Gly175 O (Asn175 in SCD),
Asp177 O1 and waters, and Ca3 by Asp107 O2, Asp182 O1, Asp182 O,
Glu184 O, and two waters.
Inhibitor Binding
The S1' specificity sites in SCD and GaCD are perhaps best described as
tunnels and differ from the smaller pockets found in fibroblast collagenase
and matrilysin. In SCD and GaCD they are roughly the same size but are
significantly different in shape. This results partly from the three residue
deletion 224–226 in GaCD relative to SCD. It also results from differences
in specific residues; thus in GaCD, Thr227 points away from the S1' site
rather than into it as found with His224 in SCD. Differences in residues
226–232 in GaCD also result in an additional bulge, and hence GaCD is
more accommodating to inhibitors with large, 'kinked' groups, in contrast to
the near-linear structure of most MMP inhibitors of SCD.29,41 Differences in
the conformation of residues 222–225, particularly Ile222 (Leu222 in SCD)
lead to a much smaller S2' site in GaCD.
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BB94 is a dipeptidic hydroxamate inhibitor (see Figure 4) which spans
the GaCD subsites S1' and S2'. The inhibitor forms a complementary strand
to 	4 and binds the zinc, similar to other hydroxamate inhibitor complexes of
MMPs. As in the U24522-SCD complex (see Figures 4 and 5a), five hydro-
gen bonds are formed between the inhibitor main chain and the protein (see
Figure 5b). One of the chelating oxygens, O3, forms hydrogen bonds with
three groups in close proximity, a water, Glu202 O1, and Ala165 O.
The P1' leucine of the inhibitor is surrounded by residues Leu164,
Val198, Pro221, and Tyr223 (as in the SCD complex), which line the entran-
ce to the deep S1' subsite. The P2' phenylalanine of the inhibitor forms con-
tacts with Leu163 and Ile222 which line the shallow S2' subsite. As can be
seen from Figure 2, these residues are different in SCD and the other ma-
trixins.
In order to gauge the relative size and shape of the S1' site, inhibitor
INH-I from its complex with SCD38 (see Figure 4) was superimposed onto
STRUCTURE OF A GELATINASE A INHIBITOR COMPLEX 583
Figure 3. The binding of BB94 with GaCD.
584 V. DHANARAJ ET AL.
Figure 4. Schematic drawings of the inhibitors: BB94, INH-I, and U24522.
Figure 5. LIGPLOT 47 of the active site of: (a) SCD complexed with U24522; (b)
GaCD complexed with BB94; (c) INH-I superimposed on GaCD. The program
HBPLUS48 was used to calculate hydrogen bonds and hydrophobic contacts between
ligand and protein using the default criteria. The hydrophobic contacts are repre-
sented as spokes protruding from a ligand atom to a protein atom or residue (deno-
ted as an arc). Spokes radiating toward the ligand indicate a potential interaction.
The zinc ions and water molecules and their subsequent bonding interactions are
not shown. 
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(b)
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(c)
the active site of GaCD (see Figure 5c). The inhibitor maintains the hydro-
gen bonding of the corresponding SCD structure, and makes a new contact
between N1 and Ile222 O. The inhibitor also makes good hydrophobic con-
tacts in the S1' site with Pro221, Tyr223, Leu218, Leu197, and Ile222
(Leu222 in SCD) as in the SCD complex of INH-I,38 along with Leu163
(Val163 in SCD) in the S2' site. However, there appears to be no / reduced
contact with His201, Phe232, His224, and Leu226 (the last two being part
of the 3-residue deletion in the sequence of GaCD relative to SCD).
GaCD and SCD appear to have larger S1' sites compared to the other
matrix metalloproteinases for which crystal structures are available. In the
fibroblast collagenases (1FBL and 1HFC), the S1' site is significantly
smaller due to the fact that Arg214 (collagenase numbering) impinges on
this area and would clash with the piperidine ring and the distal phenyl
group of INH-I. A similar clash with Tyr214 would occur with the inhibitor
in matrilysin (1MMP). In neutrophil collagenase (1MMB), Arg222 (collage-
nase numbering) would clash with the tip of the distal phenyl ring of the in-
hibitor, implying that its S1' site is deeper than in the fibroblast collage-
nases and matrilysin but smaller than in stromelysin and gelatinase.
Crystal Packing
In some SCD complexes26,29,38 the D153FYP residues are part of an ex-
posed loop which binds into the non-prime substrate binding site of a neigh-
bouring SCD molecule related by a non-crystallographic 2-fold axis. Inter-
estingly the equivalent sequence in GaCD, D153GYP, is also involved in
intramolecular interactions.
The intermolecular packing leads to large solvent channels in the crys-
tal lattice, one of which lies in the centre of the unit cell, parallel to the 41
axis along c. It is interesting to note that the active site of GaCD, including
some of the inhibitor side chains, lead directly into this channel.
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kompleksirane hidroksamatnim inhibitorom
Venugopal Dhanaraj, Mark G. Williams, Qi-Zhuang Ye, Franck Molina,
Linda L. Johnson, Daniel F. Ortwine, Alexander Pavlovsky, J. Ron Rubin,
Richard W. Skeean, Andy D. White, Christine Humblet, Donald J. Hupe
i Tom L. Blundell
Gelatinaza A klju~ni je enzim u skupini matri~nih metaloproteinaza (matriksi-
na) koje su uklju~ene u degradaciju izvanstani~ne matrice. Kako je taj proces sa-
stavni dio metastaze i angiogeneze tumorne stanice, gelatinaza je va`na meta pri
terapiji. Rentgenska kristalna struktura kataliti~kog podru~ja gelatinaze A (GaCD)
kompleksiranog hidroksamatnim inhibitorom, batimastatom (BB94), pokazuje ak-
tivno mjesto s velikim S1' specifi~nim d`epom. Struktura je sli~na prethodno rije{e-
nim strukturama kataliti~kog podru~ja stromelizina (SCD), ali s razlikama u VR1 i
VR2, dvama povr{inski izlo`enim petljama na svakoj strani prolaza prema aktivnom
mjestu. Usporedba GaCD s drugim ~lanovima skupine matri~nih metaloproteinaza
isti~e o~uvanje klju~nih sekundarnih strukturnih elemenata i zna~ajnu razliku u
specifi~nom d`epu, a to su ona znanja koja }e pove}ati mogu}nosti oblikovanja svoj-
stvenih inhibitora za tu va`nu antitumornu metu.
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